Phase II Trial of Nivolumab and Ipilimumab in Kidney Transplant Recipients with Metastatic Skin Cancer
A phase II trial is underway testing nivolumab and ipilimumab combined with sirolimus and prednisone in kidney transplant recipients with unresectable or metastatic skin cancer.
Phase II
Oncology / Immunotherapy
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
This phase II trial represents a significant advancement in the treatment of metastatic skin cancer in kidney transplant recipients, a population often underserved in oncology. Positive outcomes could reshape treatment protocols and enhance competitive positioning in both oncology and transplant medicine.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any changes in treatment guidelines for skin cancer in transplant recipients.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.